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Circulating Haptoglobin and 
Metabolic Syndrome in Renal 
Transplant Recipients
Isidor Minović1,2,3, Michele F. Eisenga1, Ineke J. Riphagen1, Else van den Berg1, Jenny 
Kootstra-Ros3, Anne-Roos S. Frenay4, Harry van Goor4, Gerald Rimbach5, Tuba Esatbeyoglu5, 
Andy P. Levy6, Carlo AJM Gaillard1, Johanna M. Geleijnse7, Manfred L. Eggersdorfer8, Gerjan J. 
Navis1, Ido P. Kema3 & Stephan J. L. Bakker1,2
Haptoglobin (Hp) is an acute phase protein that has recently been linked to components of the 
metabolic syndrome (MetS). We aimed to evaluate Hp as marker of MetS, and to assess its association 
with long-term outcome in renal transplant recipients (RTR). We measured plasma Hp in a prospective 
cohort of 699 stable RTR and 149 healthy controls. Median plasma Hp concentration in RTR was 1.4 
[interquartile range (IQR), 1.0–1.8] g/L, which was higher compared to 1.1 [0.9–1.4] g/L in controls 
(P < 0.001). Hp was independently associated with the MetS (β = 0.10) (P = 0.005). During follow-up 
of 5.4 [4.8–6.1] years, 150 (21%) recipients died, of whom 60 (9%) due to cardiovascular causes, and 83 
(12%) RTR developed graft failure. High (≥2.0 g/L) and low (≤0.9 g/L) plasma Hp were associated with 
increased risk of mortality (HR’s 2.3 [1.3–4.1] and 1.9 [1.0–3.5], resp.), predominantly cardiovascular. 
The association of high Hp lost significance upon adjustment for inflammation markers (HR 1.5 
[0.8–2.7]), while low Hp was independently associated with mortality (HR 2.2 [1.2–4.0]). Hp was not 
associated with graft failure (P = 0.49). In conclusion, plasma Hp is independently associated with MetS 
in RTR. Importantly, high and low Hp are associated with increased mortality risk, independent of MetS.
Haptoglobin (Hp) is a hepatic glycoprotein that is traditionally used to monitor in vivo hemolysis1. As such, Hp is 
assessed in transplant recipients as marker of calcineurin-induced microangiopathy short after transplantation. 
However, the role of Hp in transplant recipients under non-hemolytic circumstances, e.g. late after transplanta-
tion, has not been fully evaluated.
Previous studies describing the non-hemolytic significance of Hp have primarily been cross-sectional in 
nature and have mainly focused on the role of Hp in inflammation2–4. These studies have established Hp as a pos-
itive acute phase protein as a result of induced gene transcription by pro-inflammatory cytokines.
Besides inflammation, Hp has recently gained additional attention as it has been related to key components of 
the metabolic syndrome (MetS)5–11. The MetS is increasingly prevalent among renal transplant recipients (RTR) 
where it has been found to be an independent risk factor for development of post-transplantation diabetes mel-
litus, cardiovascular disease, mortality, and graft failure12,13. Since Hp has been related to key components of 
the MetS, Hp could possibly be interpreted as a marker of the MetS. However, as the MetS per se is associated 
with inflammation14,15, it is difficult to distinguish to what extent the previously found associations of Hp with 
components of the MetS are attributable to inflammation. Furthermore, it is not known whether Hp is associated 
with long-term outcome in RTR and it is also not known whether potential prospective associations of Hp are 
influenced by the MetS or inflammation.
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In this study, we therefore aimed to cross-sectionally evaluate Hp as marker of the MetS, and to prospec-
tively assess the association of Hp with long-term outcome in RTR, while taking into account the MetS and 
inflammation.
Results
Baseline Characteristics. Median Hp concentration in RTR (age 53 ± 13 years, 57% male) was 1.4 [1.0–
1.8], which was significantly higher compared to 1.1 [0.9–1.4] g/L in healthy controls (age 52 ± 10 years, 52% 
male) (P < 0.001). In multivariable linear regression models, this difference in Hp remained significant after 
adjustment for age, sex, smoking, Hp genotype, estimated glomerular filtration rate (eGFR), and high-sensitivity 
C-reactive protein (hs-CRP) (P = 0.002). A list of the available baseline characteristics of healthy controls can be 
found in Supplementary Table 1.
Median time between transplantation and inclusion of RTR in the study was 5.4 [1.9–12.0] years. Baseline 
characteristics for the total RTR cohort and across Hp quintiles are shown in Table 1. In RTR at baseline, Hp was 
positively associated with age, weight, body mass index (BMI), waist circumference, proteinuria, thrombocytes, 
heart rate, use of antihypertensive drug, hs-CRP, procalcitonin, low density lipoprotein (LDL) cholesterol, triglyc-
erides, use of statin, Hp 1–2 genotype, serum glucose, HbA1c, diabetes, use of antidiabetic drug, alkaline phos-
phatase, gamma glutamyl transferase, and dose of prednisolone (all P ≤ 0.05). Inverse associations were observed 
between Hp and eGFR, mean corpuscular volume (MCV), total hemoglobin (Hb), vitamin B6, serum albumin, 
high density lipoprotein (HDL)-cholesterol, Hp 2–2 genotype, serum iron, transferrin saturation (TSAT), and 
aspartate aminotransferase (ASAT) (all P ≤ 0.01). The MetS was present in 456 (65%) of 699 RTR and was posi-
tively associated with circulating Hp (P < 0.001).
Data from univariable and multivariable linear regression models demonstrating the associations of Hp with 
components of the MetS, are presented in Table 2. Adjustment for age, sex, smoking status, Hp genotype, eGFR, 
proteinuria, and use of prednisolone lowered the standardized beta of antihypertensive drug use by 38%, but did 
not materially affect the associations of Hp with other components of the MetS. However, additional adjustment 
for hs-CRP, procalcitonin, and serum albumin lowered the standardized betas of the association of Hp with waist 
circumference, triglycerides, serum glucose, antidiabetic drug use, and the MetS overall by 45%, 31%, 42%, 21%, 
and 29%, respectively. Conversely, adjustment for the inflammation parameters increased the standardized beta 
of HDL-cholesterol and statin use by 54% and 75%, respectively. Importantly, in this multivariable model Hp 
remained associated with components of the MetS (P < 0.05), as with the MetS overall (P = 0.005).
Hp and Long-Term Outcome. During follow-up of median 5.3 [4.8–6.1] years, 150 out of 699 (21%) RTR 
died, of whom 60 (9%) due to a cardiovascular cause. In the same period, 83 out of 699 (12%) RTR experienced 
graft failure.
In age- and sex-adjusted Cox regression models, high (≥2.0 g/L) and low (≤0.9 g/L) circulating Hp concen-
trations were associated with increased risk of all-cause mortality, Fig. 1A and Table 3. The association of high 
Hp with mortality, furthermore, was independent of age, sex (model 1), smoking, eGFR, proteinuria (model 2), 
Hp genotype, use of prednisolone (model 3), and BMI, vitamin B6 (model 4). Adjustment for the components 
of the MetS, waist circumference, systolic blood pressure (SBP), diastolic blood pressure (DBP), use of antihy-
pertensive drugs, HDL-cholesterol, triglycerides, use of statins, serum glucose, and use of antidiabetic drugs, 
lowered the hazard ratio (HR) of the fifth quintile by 14% to a significant HR of 1.8 [1.0–3.2] (model 5), as shown 
in Table 3. Moreover, adjustment for hs-CRP, procalcitonin, and serum albumin further lowered the HR by 29% 
to a non-significant value of 1.5 [0.8–2.7] (model 6). Adjustment for liver function parameters (model 7), and 
oxidative stress parameters (model 8) did not materially change the association of high Hp and mortality. In con-
trast, the association between low circulating Hp concentrations and all-cause mortality, Fig. 1B and Table 3, was 
independent of the potential confounders.
Analyses with cardiovascular mortality revealed similar, but higher point estimates for both the fifth and the 
first Hp quintile across Cox regression models, Table 3. Moreover, adjustment for potential confounders affected 
the associations of the fifth Hp quintile with cardiovascular mortality in a similar fashion as associations with 
all-cause mortality.
The continuous, crude association of Hp with graft failure did not achieve significance (P = 0.49). Exclusion of 
subjects with hemolytic plasma, i.e. 7 RTR, did not materially affect the Cox regression results.
Discussion
In this study, we showed that circulating Hp under non-hemolytic conditions is associated with components of 
the MetS, independent of hs-CRP, procalcitonin, and serum albumin, in RTR. Furthermore, we identified that 
high and low circulating Hp concentrations are associated with an increased risk of all-cause and cardiovascular 
mortality in this patient setting. While the association of high Hp is attenuated when taking into account inflam-
mation, as measured by hs-CRP, procalcitonin, and serum albumin, the association of low Hp with mortality was 
independent of potential confounders.
Median circulating Hp concentrations in healthy controls and RTR were in line with previous reports16–18. 
Furthermore, the high prevalence of the MetS among RTR in the present study agreed with previously published 
literature, which showed that the MetS is present in up to 63% of stable RTR19–21.
The exact involvement of Hp as marker of inflammation and adiposity in the MetS is currently unclear11. 
Studies have shown that production of Hp by adipocytes from white adipose tissue is induced by the 
pro-inflammatory factors interleukin-6 and tumor necrosis factor α11. This observation could explain why in 
the present study adjustment for hs-CRP, procalcitonin, and serum albumin accounted for a relevant part of the 
association between Hp, waist circumference, and the MetS overall. Notwithstanding, the associations between 
Hp, waist circumference, and the MetS remained significant after taking into account inflammation. To our 
www.nature.com/scientificreports/















Q5 ≥ 2.0 g/L 
(n = 127) Ptrend
Demographics
Age, years 53 ± 13 50 ± 13 51 ± 13 54 ± 13 54 ± 12 56 ± 13 <0.001
Male gender, n (%) 398 (57) 74 (55) 80 (54) 76 (61) 95 (58) 73 (57) 0.22
Weight, kg 80 ± 17 75 ± 14 81 ± 16 80 ± 18 83 ± 16 83 ± 16 <0.001











BMI<21 kg/m2, n (%) 58 (8) 18 (13) 16 (11) 5 (4) 12 (7) 7 (6) 0.01
Waist circumference, cm 101 ± 11 97 ± 9 101 ± 11 100 ± 10 102 ± 10 105 ± 12 <0.001
Smoking status, n (%)
 Current 91 (13) 11 (8) 19 (13) 12 (10) 26 (16) 18 (14)
 Past 322 (46) 62 (46) 63 (42) 65 (52) 60 (37) 69 (54) 0.26
 Never 294 (42) 62 (46) 67 (45) 46 (37) 77 (47) 41 (32) 0.07
 Time since Rtx, years 5.4 [1.9–12.0] 5.8 [3.3–9.3] 5.3 [1.3–10.9] 5.1 [1.5–10.7] 5.1 [1.5–12.0] 6.1 [2.8–13.9] 0.60
 eGFR, mL/min/1,73 m2 45 ± 19 48 ± 19 46 ± 17 46 ± 18 43 ± 20 42 ± 19 0.002
 Proteinuria, n (%) 161 (23) 23 (17) 28 (19) 24 (19) 44 (27) 40 (31) 0.001
 Rejection, n (%) 189 (27) 32 (24) 39 (26) 30 (24) 42 (26) 42 (33) 0.14
 Thrombocytes, 10E9/L 237 ± 69 218 ± 59 228 ± 64 235 ± 65 244 ± 68 259 ± 83 <0.001
 MCV, fL 90.4 ± 5.9 91.1 ± 5.9 90.4 ± 5.9 90.7 ± 5.9 90.8 ± 6.1 89.3 ± 5.6 0.001




[5.9–14.7] 8.4 [5.6–13.4] 8.9 [5.2–12.9] 8.9 [6.5–15.6]
10.5 
[5.8–17.3] 8.9 [6.1–16.3] 0.14
 Venous pH 7.37 ± 0.04 7.37 ± 0.04 7.40 ± 0.04 7.37 ± 0.04 7.36 ± 0.04 7.37 ± 0.04 0.53
 Venous HCO3−, mmol/L 24.6 ± 3.1 24.5 ± 3.1 24.8 ± 3.1 25.1 ± 3.0 24.5 ± 3.2 24.2 ± 2.9 0.23
Dietary intake and nutritional status
Total protein intake, g/d 82 ± 20 82 ± 21 83 ± 20 81 ± 20 83 ± 16 83 ± 16 0.77
Animal protein intake, g/d 51 ± 15 50 ± 15 52 ± 16 52 ± 14 52 ± 15 52 ± 15 0.37
Plant protein intake, g/d 31 ± 10 32 ± 11 31 ± 10 30 ± 10 30 ± 9 29 ± 9 0.05
Energy intake, kCal/d 2172 ± 640 2220 ± 679 2193 ± 613 2142 ± 605 2167 ± 576 2093 ± 627 0.17






[210–350] 292 [218–396] 0.29
Vitamin B6, nmol/L 29 [17–50] 31 [17–50] 33 [21–57] 30 [18–48] 27 [16–47] 23 [13–47] 0.001
Folic acid, nmol/L 18 [14–26] 18 [14–26] 19 [14–27] 19 [13–25] 18 [14–26] 18 [14–28] 0.67
Cardiovascular parameters
SBP, mmHg 136 ± 18 133 ± 17 137 ± 16 138 ± 19 135 ± 18 137 ± 17 0.29
DBP, mmHg 83 ± 11 81 ± 11 85 ± 11 83 ± 11 82 ± 12 82 ± 9 0.58
Heart rate, bpm 69 ± 12 66 ± 10 68 ± 12 69 ± 14 69 ± 11 72 ± 12 <0.001
Use of antihypertensive 
drug, n (%) 615 (88) 108 (80) 131 (88) 110 (89) 148 (91) 120 (94) <0.001
Hs–CRP, mg/L 1.6 [0.7–4.6] 0.8 [0.4–1.8] 1.3 [0.6–2.5] 1.5 [0.7–3.3] 1.8 [0.8–4.8] 6.0 [2.1–13.6] <0.001








[0.03–0.07] 0.06 [0.03–1.0] <<0.001
Serum albumin, g/L 43.0 ± 2.9 43.4 ± 3.2 43.4 ± 2.6 43.5 ± 2.9 42.7 ± 2.9 41.6 ± 3.3 <0.001
Total cholesterol, mmol/L 5.1 ± 1.1 4.9 ± 1.0 5.1 ± 1.1 5.1 ± 1.1 5.3 ± 1.1 5.2 ± 1.3 0.05
HDL-cholesterol, mmol/L 1.4 ± 0.5 1.5 ± 0.5 1.4 ± 0.5 1.4 ± 0.5 1.4 ± 0.5 1.3 ± 0.4 <0.001
LDL-cholesterol, mmol/L 2.9 [2.3–3.5] 2.7 [2.2–3.3] 3.0 [2.4–3.4] 2.9 [2.5–3.5] 2.9 [2.3–3.7] 2.8 [2.2–3.7] 0.03
Triglycerides, mmol/L 1.7 [1.3–2.3] 1.4 [1.1–1.9] 1.6 [1.2–2.3] 1.7 [1.2–2.2] 1.7 [1.3–2.5] 2.1 [1.5–2.9] <0.001
Use of statin, n (%) 370 (53) 69 (51) 67 (45) 64 (52) 85 (52) 84 (66) 0.01
MetS, n (%) 456 (65) 70 (52) 95 (64) 79 (64) 113 (69) 99 (77) <0.001
Hemolytic index > 20, n (%) 7 (1) 1 (1) 1 (1) 1 (1) 2 (1) 1 (1) 0.73
Hp 1-1 genotype 126 (18) 9 (7) 12 (8) 31 (25) 33 (20) 36 (28)
Hp 1-2 genotype 350 (50) 55 (41) 75 (50) 69 (56) 86 (53) 63 (49) 0.004
Hp 2-2 genotype 231 (33) 70 (52) 61 (41) 24 (19) 44 (27) 29 (23) <0.001
Glucose homeostasis parameters
Serum glucose, mmol/L 5.3 [4.8–6.0] 5.1 [4.7–5.7] 5.2 [4.8–6.0] 5.2 [4.7–5.8] 5.3 [4.8–6.2] 5.4 [4.8–7.0] 0.001
HbA1c, n (%) 6.0 ± 0.8 5.8 ± 0.8 5.9 ± 0.6 5.9 ± 0.7 6.1 ± 0.8 6.5 ± 1.1 <0.001
Continued
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knowledge, one non-inflammation related factor has been shown to control Hp gene transcription in adipocytes. 
It has been demonstrated that dexamethasone is able to increase Hp mRNA levels in cultured adipocytes by 
approximately threefold, compared to control treatment22. While data from this in vitro study were limited to 
dexamethasone, it is conceivable that other corticosteroids have similar effects on Hp production by adipocytes 















Q5 ≥ 2.0 g/L 
(n = 127) Ptrend
Diabetes, n (%) 168 (24) 22 (16) 27 (18) 24 (19) 22 (26) 55 (43) <0.001
Use of antidiabetic drug, 
n (%) 112 (16) 16 (12) 15 (10) 17 (14) 24 (15) 38 (30) <0.001
Iron metabolism parameters
Serum iron, µmol/L 15.3 ± 6.0 16.9 ± 7.1 15.6 ± 5.6 15.9 ± 6.4 14.9 ± 5.1 12.9 ± 5.1 <0.001
Transferrin, g/L 2.5 ± 0.3 2.5 ± 0.3 2.6 ± 0.5 2.5 ± 0.4 2.5 ± 0.4 2.4 ± 0.4 0.19
TSAT, % 25.1 ± 11.7 27.9 ± 11.9 25.2 ± 10.4 26.2 ± 11.0 24.8 ± 10.2 21.6 ± 8.8 <0.001
Liver function parameters
ALAT, U/L 19 [14–26] 19 [14–28] 19 [15–27] 19 [15–24] 19 [15–24] 19 [14–27] 0.60
ASAT, U/L 22 [18–27] 24 [19–30] 23 [19–27] 22 [18–27] 21 [18–26] 20 [16–26] <0.001
Alkaline phosphatase, U/L 67 [53–83] 63 [48–81] 65 [53–79] 66 [54–81] 69 [57–87] 70 [56–93] 0.001
Gamma glutamyl 
transferase, U/L 26 [19–41] 26 [17–41] 25 [17–46] 25 [19–35] 28 [20–39] 30 [19–46] 0.03
Antioxidant status parameters
Plasma MDA, µmol/L 2.6 [1.9–3.8] 2.8 [2.0–4.1] 2.6 [2.1–3.7] 2.3 [1.8–3.1] 2.4 [1.9–4.4] 2.4 [1.8–3.7] 0.41
Urinary MDA excretion, 
µmol/24 h
9.7 
[5.9–15.7] 9.6 [6.0–14.2] 9.3 [5.6–15.9] 9.6 [6.2–16.0]
10.3 
[6.0–15.4] 9.4 [5.5–16.1] 0.12
R-SH/total protein, mM/g 1.83 ± 0.67 1.80 ± 0.64 1.91 ± 0.74 1.81 ± 0.59 1.75 ± 0.72 1.90 ± 0.60 0.80
Immunosuppression
Use of calcineurin inhibitor, n (%)
 -Cyclosporine 273 (39) 46 (34) 61 (41) 50 (40) 70 (43) 49 (38) 0.33
 -Tacrolimus 133 (19) 26 (19) 36 (24) 19 (15) 26 (16) 19 (15) 0.59
 Use of proliferation 
inhibitor, n (%) 580 (83) 116 (86) 125 (84) 104 (84) 135 (83) 102 (80) 0.16
 Prednisolone 
dose < 10 mg/24 h, n (%) 288 (41) 64 (47) 73 (49) 49 (40) 60 (37) 42 (33) 0.001
Table 1. Baseline characteristics of 699 renal transplant recipients, stratified by haptoglobin quintiles. Hp, 
haptoglobin; BMI, body mass index; Rtx, renal transplantation; eGFR, estimated glomerular filtration rate; 
MCV, mean corpuscular volume; Hb, hemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
hs-CRP, high-sensitivity C-reactive protein; HDL, high density lipoprotein; LDL, low density lipoprotein; MetS, 
metabolic syndrome; Hp, haptoglobin; TSAT, transferrin saturation, ALAT, alanine aminotransferase; ASAT, 
aspartate aminotransferase; MDA, malondialdehyde; R-SH, serum free thiols.







Waist circumference, cm 0.22 <0.001 0.22 <0.001 0.12 0.001
SBP, mmHg 0.03 0.49 −0.03 0.41 0.01 0.94
DBP, mmHg 0.01 0.81 −0.02 0.71 −0.01 0.86
Antihypertensive drugs, n (%) 0.16 <0.001 0.10 0.01 0.08 0.02
HDL-cholesterol, mmol/L −0.12 0.002 −0.13 0.001 −0.06 0.14
Triglycerides, mmol/L 0.19 <0.001 0.16 <0.001 0.11 0.002
Statin, n (%) 0.09 0.02 0.08 0.04 0.14 <0.001
Serum glucose, mmol/L 0.11 0.005 0.12 0.002 0.07 0.05
Antidiabetic drugs, n (%) 0.15 <0.001 0.14 <0.001 0.11 0.002
MetS, n (%) 0.16 <0.001 0.14 <0.001 0.10 0.005
Table 2. Univariable and multivariable associations of MetS components with Hp. *Crude associations; 
**adjusted for age, sex, smoking, Hp genotype, eGFR, proteinuria, and use of prednisolone; ***as model 
2, additionally adjusted for hs-CRP, procalcitonin, and serum albumin. Stand. beta, standardized beta; 
SBP, systolic blood pressure; DBP, diastolic bloodpressure; HDL, high-density lipoprotein; MetS, metabolic 
syndrome.
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between use of prednisolone and circulating Hp. However, adjustment for use of prednisolone did not materially 
affect the associations between Hp and components of the MetS, including waist circumference.
Prospectively, we identified an association between high circulating Hp (≥2.0 g/L) and mortality, in particular 
cardiovascular mortality. Indeed, high plasma Hp has previously been associated with development of coronary 
artery disease, possibly through atherosclerotic progression23. In the present study, both the associations of cir-
culating Hp with all-cause and with cardiovascular mortality were weakened after adjustment for MetS, and lost 
significance after adjustment for inflammation. Our data thus suggest that in this patient setting Hp is, prospec-
tively, a marker of inflammation rather than a marker of the MetS.
Interestingly, the associations between low circulating Hp concentrations and mortality were independent of 
the potential confounders. The causes for these prospective association are unknown, as we have accounted for 
most factors that have been associated with low circulating Hp concentrations by virtue of the stable nature of our 
RTR cohort and by controlling for the concerning variables in the statistical analyses. For example, hemolysis, 
which rapidly decreases circulating Hp concentrations24, is virtually absent in our stable RTR cohort and could 
thus not explain the higher mortality risk for subjects with lower circulating Hp. Other circumstances that are 
associated with decreased circulating Hp, include Hp genotype7 and bone marrow failure25. However, adjustment 
for Hp genotype in the prospective analyses had no material effect. Furthermore, if low Hp is a consequence of 
bone marrow failure, then a positive relationship between circulating Hp and Hb would be anticipated. Instead, 
we observed an inverse relationship between Hp and Hb, which argues against ineffective erythropoiesis due to 
bone marrow failure. Alternatively, low circulating concentration of Hp might be the consequence of malnutri-
tion or liver dysfunction16,26. Of the parameters that indicate nutritional status, Hp was associated with BMI and 
vitamin B6. While RTR with low Hp also had lower BMI, and thus might have had a poorer nutritional status, 
they discordantly had higher plasma vitamin B6 concentrations, which may be indicative of better nutritional 
status. Similarly conflicting results were found for the liver function parameters, where ASAT and gamma glu-
tamyl transferase were inversely associated, while alkaline phosphatase was positively associated and alanine 
aminotransferase (ALAT) was not associated with circulating Hp. Interestingly, adjustment for BMI, vitamin 
B6, and liver function parameters did not noticeably affect the association of low Hp with mortality. Irrespective 
of the cause, low circulating Hp concentrations could result in impaired scavenging of the redox active free Hb, 
which could consequently amplify Hb-mediated oxidative damage to the vasculature27. However, RTR with low 
circulating Hp concentrations (≤0.9 g/L) had similar values of oxidative stress markers as compared to RTR with 
Hp > 0.9 g/L and adjustment for these markers did not materially affect the association between low circulating 
Hp and mortality, thus discrediting the hypothesis that RTR with low circulating Hp concentrations experienced 
increased oxidative stress and that this might have played a role in the prospective associations. Together, the 
Figure 1. Age- and sex-adjusted (A) and fully adjusted (B) associations of Hp with all-cause mortality in RTR. 
The histograms represent frequencies of plasma Hp concentrations, whereas the black lines show the risk (HR) 
of all-cause mortality. The gray areas represent the appropriate 95% CI’s. The fully adjusted association was 
adjusted for age, sex, smoking, eGFR, proteinuria, Hp genotype, use of prednisolone, BMI, vitamin B6, waist 
circumference, triglycerides, HDL-cholesterol, use of statins, SBP, DBP, use of antihypertensive drugs, blood 
glucose, use of antidiabetic drugs, hs-CRP, procalcitonin, serum albumin, ALAT, ASAT, alkaline phosphatase, 
gamma glutamyl transferase, plasma MDA, urinary MDA excretion, and serum free thiols.
www.nature.com/scientificreports/
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results of these analyses suggest that the association of low Hp with mortality may reflect a constitutional state 
predisposing to increased susceptibility to cardiovascular disease.
Strengths of this study include the large cohort size of this specific population consisting of well-characterized, 
stable RTR, in which no cases were lost to follow-up. Extensive information on serum and urinary parameters 
allowed adjustment for many potential confounders. In addition, the novel ELISA assay used to determine Hp 
genotype is validated and more sensitive than conventional methods. However, we also acknowledge that this 
study has limitations. First, the observational study design precludes conclusions on causality. Second, we did not 
have data on components of the MetS in healthy controls. Therefore, we were unable to assess factors that could 
explain the potential difference in prevalence of the MetS between healthy controls and RTR. Third, this is a single 
center study of almost only Caucasian subjects. As a consequence, our results may not be representative for other 
populations. However, a study involving stable heart transplant recipients reported similar circulating Hp con-
centrations, which conceivably indicates that increased Hp might be similarly relevant in other stable transplant 
populations28. Future research should address this issue in other transplant populations late after transplantation.
To conclude, Hp is associated with the MetS, independent of inflammation, in RTR. Importantly, both low and 
high Hp are associated with an increased risk of mortality, predominantly cardiovascular. The association of high 
Hp with mortality was independent of components of the MetS, but was in part explained by inflammation. This 
suggests that, prospectively, high Hp can be considered a valid marker of inflammation in RTR. Furthermore, the 
prospective associations of low Hp were independent of potential confounders, suggesting that constitutionally 
low Hp is an independent risk factor for mortality in RTR. Further research is warranted to investigate the valid-
ity of Hp as marker of the MetS in other populations, including non-renal transplant recipients and the general 
population, and to identify the mechanisms that underlie the association of low circulating Hp concentrations 
with long-term mortality in RTR.
Subjects and Methods
Study Population. This prospective cohort study was based on a previously described, well-characterized 
set of 707 RTR29,30. Briefly, this cohort included RTR (aged ≥ 18 years) who visited the outpatient clinic of the 
University Medical Center Groningen (UMCG), Groningen, the Netherlands, between November 2008 and June 
2011 and who had a graft that had been functioning for at least 1 year with no history of alcohol and/or drug 
addiction. Of 707 RTR that provided written informed consent, we excluded subjects with missing biomaterial 
(i.e. 8 cases) from the statistical analyses, which resulted in 699 cases eligible for analyses. As control group 
Hp Quintiles (number of events/number of cases)
I (27/135) II (23/149)
III 
(19/124) IV (41/163) V (40/128)
All-cause mortality HR [95% CI] P Value HR [95% CI] P Value Reference HR [95% CI] P Value HR [95% CI] P Value
Model 1 1.9 [1.0–3.5] 0.03 1.3 [0.7–2.5] 0.34 1.00 1.9 [1.1–3.4] 0.02 2.3 [1.3–4.1] 0.003
Model 2 2.1 [1.2–3.9] 0.01 1.2 [0.6–2.3] 0.57 1.00 1.6 [0.9–2.7] 0.13 2.1 [1.2–3.6] 0.01
Model 3 2.1 [1.2–3.9] 0.02 1.2 [0.7–2.3] 0.50 1.00 1.5 [0.8–2.6] 0.17 1.9 [1.1–3.3] 0.03
Model 4 2.0 [1.1–3.8] 0.02 1.2 [0.6–2.2] 0.66 1.00 1.5 [0.9–2.7] 0.14 2.1 [1.2–3.6] 0.01
Model 5 2.1 [1.1–3.8] 0.02 1.2 [0.7–2.3] 0.53 1.00 1.5 [0.9–2.7] 0.15 1.8 [1.0–3.2] 0.04
Model 6 2.2 [1.2–4.0] 0.02 1.2 [0.7–2.2] 0.59 1.00 1.4 [0.8–2.4] 0.27 1.5 [0.8–2.7] 0.18
Model 7 2.2 [1.2–3.9] 0.01 1.2 [0.6–2.3] 0.55 1.00 1.5 [0.8–2.6] 0.18 1.9 [1.1–3.3] 0.03
Model 8 2.2 [1.2–4.0] 0.01 1.2 [0.7–2.3] 0.52 1.00 1.6 [0.9–2.8] 0.11 2.1 [1.2–3.6] 0.01
Cardiovascular mortality I (11/135) II (5/149) III (6/124) IV (19/163) V (19/128)
Model 1 2.3 [0.9–6.3] 0.10 0.9 [0.3–2.9] 0.83 1.00 2.5 [1.0–6.3] 0.06 3.2 [1.3–8.1] 0.01
Model 2 2.7 [1.0–7.3] 0.06 0.8 [0.2–2.6] 0.68 1.00 1.9 [0.7–4.8] 0.20 2.8 [1.1–7.0] 0.03
Model 3 2.8 [1.0–7.8] 0.04 0.8 [0.2–2.7] 0.72 1.00 1.8 [0.7–4.5] 0.24 2.5 [1.0–6.4] 0.05
Model 4 2.7 [0.9–7.5] 0.07 0.7 [0.2–2.5] 0.62 1.00 2.0 [0.8–5.1] 0.16 2.9 [1.2–7.4] 0.02
Model 5 2.8 [1.0–7.8] 0.05 0.8 [0.2–2.7] 0.72 1.00 1.8 [0.7–4.7] 0.23 2.5 [1.0–6.4] 0.05
Model 6 2.9 [1.0–8.2] 0.04 0.8 [0.2–2.7] 0.75 1.00 1.8 [0.6–4.3] 0.30 1.9 [0.7–4.9] 0.22
Model 7 2.8 [1.0–7.6] 0.05 0.7 [0.2–2.5] 0.63 1.00 1.7 [0.7–4.4] 0.26 2.4 [0.9–6.1] 0.07
Model 8 2.8 [1.0–7.7] 0.05 0.8 [0.2–2.6] 0.72 1.00 2.0 [0.8–5.1] 0.15 2.8 [1.1–7.0] 0.03
Table 3. Cox regression analyses for the prediction of patient all-cause and cardiovascular mortality based 
on plasma Hp concentrations. Model 1, adjusted for age, sex; model 2, as model 1, additionally adjusted 
for smoking, eGFR and proteinuria; model 3, as model 2, additionally adjusted for Hp genotype and use of 
prednisolone; model 4, as model 2, additionally adjusted for BMI, vitamin B6; model 5, as model 2, additionally 
adjusted for waist circumference, SBP, DBP, use of antihypertensive drugs, HDL-cholesterol, triglycerides, 
use of statins, serum glucose, use of antidiabetic drugs; model 6, as model 2, additionally adjusted for hs-
CRP, procalcitonin, and serum albumin; model 7, as model 2, additionally adjusted for ALAT, ASAT, alkaline 
phosphatase, and gamma glutamyl transferase; model 8, as model 2, additionally adjusted for plasma MDA, 
urinary MDA excretion, and serum free thiols. Hp, haptoglobin; HR, hazard ratio; CI, confidence interval.
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reflecting the general population, we included 149 healthy kidney donors. The study protocol was approved by 
the UMCG institutional review board (METc 2008/186) and adhered to the Declarations of Helsinki and Istanbul.
Measurements. Participants were asked to collect a 24-hour urine sample on the day prior to visiting the 
outpatient clinic. Urine was collected under oil, and chlorhexidine was added as an antiseptic agent. Urinary albu-
min was quantified using nephelometry (Dade Behring Diagnostic, Marburg, Germany) and total urinary protein 
concentration was determined by means of the Biuret reaction (MEGA AU 510; Merck Diagnostica, Darmstadt, 
Germany). Proteinuria was defined as urinary protein excretion ≥0.5 g/24 h.
Upon completion of the 24-hour urine collection, blood was drawn the following morning, and venous blood 
analyses were assessed immediately thereafter by validated assays. Hp was measured using an automated turbi-
dimetric immunoassay (Roche Diagnostics, Basel, Switzerland). Vitamin B6 was measured as plasma pyridoxal 
5′-phosphate by means of a high-performance liquid chromatography (HPLC) assay31. Malondialdehyde (MDA) 
was also quantified by means of an HPLC method and free thiol groups (R-SH) were detected as described pre-
viously32,33. Free thiol groups were corrected for total serum protein (R-SH/total protein), since serum proteins 
largely determine the amounts of measurable free thiol groups. Other laboratory measurements, including blood 
counts, albumin, hs-CRP, lipids, and glucose homeostasis parameters, were performed by automated spectropho-
tometric routine laboratory methods. Free Hb was quantified in plasma as hemolytic index by a semi-quantitative 
routine laboratory method with a limit of quantification of 3 µmol/L (Roche Diagnostics, Basel, Switzerland). 
Hemolysis was identified in samples with hemolytic index > 20. Serum creatinine was determined by means of a 
modified version of the Jaffé method (MEGA AU 510; Merck Diagnostica). GFR was estimated by applying the 
Chronic Kidney Disease Epidemiology Collaboration equation34. We defined the MetS according to National 
Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol 
in Adults (ATP III) criteria35,36. In accordance with these criteria, a person has MetS when at least three of the fol-
lowing cardiovascular risk factors are present or medication to control these traits is taken: waist circumference is 
≥89 cm for women and ≥102 cm for men, triglyceride level ≥1.7 mmol/L, HDL-cholesterol level ≤1.04 mmol/L 
for men and ≤1.30 mmol/L in women, SBP ≥130 or DBP ≥85 mm Hg, and fasting blood glucose ≥5.6 mmol/L. 
Diabetes mellitus was diagnosed according to American Diabetes Association criteria as fasting plasma glucose 
concentration of at least 7.0 mmol/L or use of antidiabetic medication37. Finally, Hp genotype distributions were 
determined with a novel ELISA method, which was previously described and validated by Levy et al.38.
Statistical analyses. Data analyses were performed using SPSS 22.0 for Windows (SPSS Inc., Chicago, IL) 
and GraphPad Prism version 5.01 for Windows (GraphPad Software, San Diego, CA). Data are presented as 
mean ± SD for normally distributed data, as median [interquartile range (IQR)] for non-normally distributed 
data, and as number (percentage) for nominal data. A two-sided P < 0.05 was considered to indicate statistical 
significance.
Linear regression analyses were employed to investigate differences in Hp between healthy controls and RTR 
and to assess cross-sectional associations of log-transformed Hp with baseline variables (Ptrend). Multivariable 
linear regression models were constructed to account for potential confounders, including age, sex, smoking, Hp 
genotype, eGFR, proteinuria, use of prednisolone, and for inflammation, as assessed by hs-CRP, procalcitonin, 
and serum albumin39. Percentage change in standardized beta was calculated as: ((standardized beta after adjust-
ment – standardized beta before adjustment)/standardized beta before adjustment) × 100.
Several subjects had missing values for one or more baseline variables (i.e., age, sex, time since renal transplan-
tation (Rtx), hs-CRP, eGFR, proteinuria [<0.5%], HbA1c [4.0%], and smoking status [6.2%]). Because excluding 
subjects with missing values could result in biased prospective results, multiple imputation (fully conditional 
specification [MCMC]) was employed to obtain five imputed datasets for the Cox regression analyses40,41. Rubin’s 
rules were followed to obtain pooled estimates of the regression coefficients and their standard errors across the 
imputed datasets42.
Prospective associations were explored by means of Cox regression analysis. Prospective data are presented as 
HR [95% confidence interval]. In these analyses, associations were adjusted in a parallel fashion for potential con-
founders, including age, sex (models 1), smoking, eGFR, proteinuria (models 2), Hp genotype, use of predniso-
lone (models 3), BMI, vitamin B6 (models 4), the MetS components waist circumference, systolic blood pressure 
(SBP), diastolic blood pressure (DBP), use of antihypertensive drugs, high-density lipoprotein (HDL)-cholesterol, 
triglycerides, use of statins, serum glucose, use of antidiabetic drugs (models 6), the inflammation-related mark-
ers hs-CRP, procalcitonin, serum albumin (models 6), liver function parameters ALAT, ASAT, alkaline phos-
phatase, gamma glutamyl transferase (model 7), and plasma MDA, urinary MDA excretion, and serum free thiols 
(model 8). Cox regression models were built in a stepwise fashion to avoid over-fitting and to keep the number of 
predictors in proportion to the number of events43. Percentage change in HR was calculated as: ((HR after adjust-
ment – HR before adjustment)/(HR before adjustment-1)) × 10044. Proportionality of hazards for covariates was 
investigated by inspecting the Schoenfeld residuals.
Clinical End Points. The primary endpoints of this study were all-cause and cardiovascular mortality and 
death-censored transplant failure, defined as return to dialysis therapy or re-transplantation. The continuous 
surveillance system of the outpatient program ensures up-to-date information on patient status and cause of graft 
failure. The cause of graft failure was obtained from patient records and was reviewed by a blinded nephrologist. 
Cause of death was defined as cardiovascular in origin if death was due to cerebrovascular disease, ischemic heart 
disease, heart failure, or sudden death. Endpoints were recorded until the end of May 2013 and there was no loss 
due to follow-up for the primary endpoints.
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